Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Schellekens Kh is active.

Publication


Featured researches published by Schellekens Kh.


Drug Research | 1960

Chemistry and pharmacology of compounds related to 4-(4-hydroxy-4-phenyl-piperidino)-butyrophenone

Paul A. J. Janssen; Anton H. M. Jageneau; Schellekens Kh

SummaryHaloperidol (R 1625) is 50 to 100 times more active than chlorpromazine as an inhibitor of exploratory motor behaviour in rats. Emotional defaecation in rats is inhibited by both drugs at similar dose levels.


European Journal of Pharmacology | 1970

The pharmacology of penfluridol (R 16341) a new potent and orally long-acting neuroleptic drug

Paul A. J. Janssen; C. J. E. Niemegeers; Schellekens Kh; Fred M. Lenaerts; Frans J. Verbruggen; Jan M. Van Nueten; Wolfgang Schaper

Abstract R 16341, 4-(4-chloro- a , a , a -trifluoro-m-tolyl)-1[4,4-bis(p-fluorophenyl)butyl]-4-piperidinol is a new member of the potent and long-acting series of diphenylbutyl piperidine neuroleptics of which pimozide is the prototype. In animals the pharmacological profile of R 16341 resembles that of typical neuroleptic compounds. R 16341 is very potent by the oral route and has a longer duration of action than any other neuroloptic we have tested. At 4 times the minimum ED 50 -value of the anti-apomorphine test in dogs, R 16341 has a duration of action of about 7 days. The onset of action of R 16341 is gradual and smooth and its peak effect is generally reached 24 to 48 hr after administration. R 16341 is relatively atoxic with a safety margin of 1:1000 in rats and dogs. Qualitatively R 16341 is more closely related to haloperidol and pimozide than to chlorpromazine, the side-effect liability is expected to be lower than that of chlorpromazine, when hypotensive and autonomic side-effects are concerned and to be lower than that of haloperidol when undesirable neurological side-effects are concerned.


Cellular and Molecular Life Sciences | 1977

Oxatomide, a new orally active drug which inhibits both the release and the effects of allergic mediators.

F. Awouters; C. J. E. Niemegeers; J. Van den Berk; J.M. Van Nueten; Fred M. Lenaerts; M. Borgers; Schellekens Kh; A. Broeckaert; J. De Cree; P. A. J. Janssen

Oxatomide is a new potent inhibitor of anaphylactic and allergic reactions. After oral administration, the compound both inhibits the release of endogenous histamine and prevents the effects of exogenous histamine, at comparable doses. The combination of these effects appears to be the basis of the effectiveness of oxatomide in allergic reactions and may lead to clinical applications different from classical antihistaminics and from cromoglycate.


Nature | 1990

Potent and selective inhibition of HIV-1 replication in vitro by a novel series of TIBO derivatives.

Rudi Pauwels; Koen Andries; Jan Desmyter; Dominique Schols; Michael Joseph Kukla; Henry J. Breslin; Alfons Raeymaeckers; Jozef Van Gelder; R. Woestenborghs; J. Heykants; Schellekens Kh; Marcel Janssen; Erik De Clercq; Paul A. J. Janssen


Journal of Pharmacology and Experimental Therapeutics | 1988

Pharmacology of risperidone (R 64 766), a new antipsychotic with serotonin-S2 and dopamine-D2 antagonistic properties.

P. A. J. Janssen; C. J. E. Niemegeers; F. Awouters; Schellekens Kh; Anton A. H. P. Megens; Theo F. Meert


Drug Research | 1966

Is it possible to predict the clinical effects of neuroleptic drugs (major tranquillizers) from animal data

Paul A. J. Janssen; Niemegeers Cj; Schellekens Kh


Psychopharmacology | 1960

Chemistry and pharmacology of compounds related to 4-(4-hydroxy-4-phenyl-piperidino)-butyrophenone: Part IV influence of haloperidol (R 1625) and of chlorpromazine on the behaviour of rats in an unfamiliar ?open field? situation

Paul A. J. Janssen; Anton H. M. Jageneau; Schellekens Kh


Journal of Medicinal Chemistry | 1959

Chemistry and Pharmacology of CNS Depressants Related to 4-(4-Hydroxy-4-phenylpiperidino)butyrophenone Part I--Synthesis and screening data in mice

Paul A. J. Janssen; Corn. van De Westeringh; Anton H. M. Jageneau; Paul J. A. Demoen; Bert K. F. Hermans; Georges Henri Paul Van Daele; Schellekens Kh; Cyriel A. M. Van der Eycken; C. J. E. Niemegeers


Drug Research | 1967

Is it possible to predict the clinical effects of neuroleptic drugs (major tranquillizers) from animal data? IV. An improved experimental design for measuring the inhibitory effects of neuroleptic drugs on amphetamine-or apomorphine-induced "Cheroing" and "agitation" in rats.

Paul A. J. Janssen; Niemegeers Cj; Schellekens Kh; Lenaerts Fm


Drug Research | 1971

Etomidate, R-(+)-ethyl-1-( -methyl-benzyl)imidazole-5-carboxylate (R 16659), a potent, short-acting and relatively atoxic intravenous hypnotic agent in rats.

Paul A. J. Janssen; Niemegeers Cj; Schellekens Kh; Lenaerts Fm

Collaboration


Dive into the Schellekens Kh's collaboration.

Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Dominique Schols

Rega Institute for Medical Research

View shared research outputs
Researchain Logo
Decentralizing Knowledge